[go: up one dir, main page]

SG47501A1 - N-sulfonyl indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present - Google Patents

N-sulfonyl indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present

Info

Publication number
SG47501A1
SG47501A1 SG1996002367A SG1996002367A SG47501A1 SG 47501 A1 SG47501 A1 SG 47501A1 SG 1996002367 A SG1996002367 A SG 1996002367A SG 1996002367 A SG1996002367 A SG 1996002367A SG 47501 A1 SG47501 A1 SG 47501A1
Authority
SG
Singapore
Prior art keywords
alkyl
mono
substd
halogen
opt
Prior art date
Application number
SG1996002367A
Other languages
English (en)
Inventor
Dino Nisato
Claude Plouzane
Claudine Serradeil-Legal
Bernard Tonnerre
Jean Wagon
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG47501A1 publication Critical patent/SG47501A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG1996002367A 1991-08-02 1992-08-03 N-sulfonyl indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present SG47501A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9109908A FR2679903B1 (fr) 1991-08-02 1991-08-02 Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.

Publications (1)

Publication Number Publication Date
SG47501A1 true SG47501A1 (en) 1998-04-17

Family

ID=9415909

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996002367A SG47501A1 (en) 1991-08-02 1992-08-03 N-sulfonyl indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present

Country Status (29)

Country Link
EP (1) EP0526348B1 (xx)
JP (1) JP2633085B2 (xx)
KR (1) KR100241583B1 (xx)
AT (1) ATE163289T1 (xx)
AU (2) AU658664B2 (xx)
BR (1) BR9205336A (xx)
CA (2) CA2206776C (xx)
CZ (1) CZ288173B6 (xx)
DE (1) DE69224450T2 (xx)
DK (1) DK0526348T3 (xx)
ES (1) ES2117038T3 (xx)
FI (2) FI104069B (xx)
FR (1) FR2679903B1 (xx)
HK (1) HK1008741A1 (xx)
HU (2) HUT68927A (xx)
IL (3) IL102703A (xx)
LT (1) LT3064B (xx)
LV (1) LV10091B (xx)
MX (1) MX9204487A (xx)
MY (1) MY110517A (xx)
NO (1) NO180047C (xx)
NZ (1) NZ243795A (xx)
PH (1) PH30661A (xx)
RU (1) RU2104268C1 (xx)
SG (1) SG47501A1 (xx)
SK (1) SK283463B6 (xx)
UA (1) UA27238C2 (xx)
WO (1) WO1993003013A1 (xx)
ZA (1) ZA925781B (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
FR2756736B1 (fr) * 1996-12-05 1999-03-05 Sanofi Sa Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
CA2290748A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
CN1265669A (zh) * 1997-07-31 2000-09-06 伊兰药品公司 抑制由vla－4介导的白细胞粘着的化合物
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1001971A1 (en) * 1997-07-31 2000-05-24 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
FR2775598A1 (fr) * 1998-03-06 1999-09-10 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine
FR2778103A1 (fr) * 1998-04-29 1999-11-05 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
FR2786486B3 (fr) * 1998-11-16 2000-12-08 Sanofi Sa Procede de preparation du (2s)-1-[(2r,3s)-5-chloro-3-(2- chlorophenyl)-1-(3,4-dimethoxy benzenesulfonyl)-3-hydroxy- 2,3-dihydro-1h-indole-2-carbonyl]pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates
NZ512565A (en) 1999-01-22 2003-12-19 Elan Pharm Inc Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
ATE455106T1 (de) 1999-01-22 2010-01-15 Elan Pharm Inc Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
WO2000043415A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
GB9902461D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
FR2792834A1 (fr) * 1999-04-29 2000-11-03 Sanofi Sa Utilisation du sr 49059, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la preparation de medicaments utiles dans le traitement ou la prevention du phenomene de raynaud
FR2805536B1 (fr) * 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805992A1 (fr) * 2000-03-08 2001-09-14 Sanofi Synthelabo Compositions pharmaceutiques orales contenant des derives de n-sulfonylindoline
CA2423933A1 (en) 2000-10-17 2002-04-25 Applied Research Systems Ars Holding N.V. Pharmaceutically active sulfanilide derivatives
CA2425892A1 (en) 2000-11-28 2003-04-11 Hiroyuki Koshio 1,4,5,6-tetrahydroimidazo[4,5-d]diazepine derivative or salt thereof
JP4044740B2 (ja) * 2001-05-31 2008-02-06 信越化学工業株式会社 レジスト材料及びパターン形成方法
SI1458381T1 (sl) 2001-12-20 2006-04-30 Applied Research Systems Triazoli kot oksitocinski antagonisti
EP2402309A1 (en) 2002-05-24 2012-01-04 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
ES2311721T3 (es) * 2002-09-17 2009-02-16 F. Hoffmann-La Roche Ag Indoles sustituidos en posicion 2,4 y su empleo como moduladores de 5-ht6.
DK1587788T3 (da) * 2002-09-17 2007-09-24 Hoffmann La Roche 2,7-substituerede indoler og anvendelsen deraf som 5-HT6-modulatorer
RU2334735C2 (ru) * 2002-10-11 2008-09-27 Актелион Фармасьютиклз Лтд. Производные сульфониламиноуксусной кислоты и их применение в качестве антагонистов рецепторов орексина
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
ATE363470T1 (de) 2002-11-18 2007-06-15 Chemocentryx Inc Arylsulfonamide
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
MX2007005126A (es) * 2004-10-27 2007-07-04 Kissei Pharmaceutical Compuesto de indolina y proceso para producir el mismo.
US7727996B2 (en) 2005-09-29 2010-06-01 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
AU2006297220B8 (en) 2005-09-29 2013-01-31 Elan Pharmaceuticals, Inc. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
JP5135235B2 (ja) 2006-02-27 2013-02-06 エラン ファーマシューティカルズ，インコーポレイテッド Ｖａｌ−４によって媒介される白血球の接着を阻害するピリミジニルスルホンアミド化合物
JP2012525336A (ja) 2009-04-27 2012-10-22 エラン ファーマシューティカルズ，インコーポレイテッド α−４インテグリンのピリジノンアンタゴニスト
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
US4479963A (en) * 1981-02-17 1984-10-30 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3705934A1 (de) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
AU1154195A (en) 1995-05-04
AU691223B2 (en) 1998-05-14
LT3064B (en) 1994-10-25
BR9205336A (pt) 1993-11-16
HU211884A9 (en) 1995-12-28
CA2206776C (en) 2002-02-26
WO1993003013A1 (fr) 1993-02-18
FR2679903A1 (fr) 1993-02-05
KR100241583B1 (ko) 2000-03-02
ZA925781B (en) 1993-03-02
HUT68927A (en) 1995-08-28
JP2633085B2 (ja) 1997-07-23
DK0526348T3 (da) 1998-11-23
HU9300951D0 (en) 1993-06-28
NO180047B (no) 1996-10-28
NZ243795A (en) 1995-04-27
DE69224450T2 (de) 1998-07-30
FI107048B (fi) 2001-05-31
AU658664B2 (en) 1995-04-27
NO931262L (no) 1993-05-26
NO180047C (no) 1997-02-05
UA27238C2 (uk) 2000-08-15
RU2104268C1 (ru) 1998-02-10
CA2093221C (en) 1998-09-22
MY110517A (en) 1998-07-31
LV10091A (lv) 1994-05-10
FI104069B1 (fi) 1999-11-15
IL102703A (en) 1997-03-18
FI931476A7 (fi) 1993-04-01
IL117592A0 (en) 1996-07-23
LV10091B (en) 1995-04-20
CZ288173B6 (en) 2001-05-16
FI980175L (fi) 1998-01-27
CZ68293A3 (en) 1994-01-19
LTIP114A (en) 1994-06-15
MX9204487A (es) 1993-02-01
AU2475892A (en) 1993-03-02
JPH06501960A (ja) 1994-03-03
ES2117038T3 (es) 1998-08-01
DE69224450D1 (de) 1998-03-26
HK1008741A1 (en) 1999-05-14
IL102703A0 (en) 1993-01-14
FI931476A0 (fi) 1993-04-01
IL117592A (en) 1999-04-11
EP0526348A1 (fr) 1993-02-03
PH30661A (en) 1997-09-16
FI104069B (fi) 1999-11-15
NO931262D0 (no) 1993-04-01
SK283463B6 (sk) 2003-08-05
SK42693A3 (en) 1993-10-06
FR2679903B1 (fr) 1993-12-03
ATE163289T1 (de) 1998-03-15
CA2206776A1 (en) 1993-02-03
CA2093221A1 (en) 1993-02-03
FI980175A0 (fi) 1998-01-27
EP0526348B1 (fr) 1998-02-18

Similar Documents

Publication Publication Date Title
SG47501A1 (en) N-sulfonyl indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present
RU2005123807A (ru) Тетрагидро-4н-пиридо[1,2-а]пиримидины и родственные соединения, полезные в качестве ингибиторов вич-интегразы
PT81748A (en) Process for the preparation of novel oxetanones of novel intermediates which are usable in this process and of pharmaceutical compositions based on said oxetanones or based on precursors thereof
IL97612A0 (en) N-substituted heterocyclic derivatives,their preparation and pharmaceutical compositions containing them
TW325462B (en) Urea derivatives and the pharmaceutical composition for 5-HT antagonist
HUP9901630A2 (hu) Új indol-2,3-dion-3-oxim-származékok
BR112022023937A2 (pt) Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
NZ333926A (en) Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use
IE36710L (en) Hydrazinopyridazine derivatives
ATE189459T1 (de) Peptide mit endothelin antagonistischer aktivitaet. deren herstellung und pharmazeutische zusammensetzungen
DE60218199D1 (de) Humane wachstumshormone freisetzende hormonanaloge, deren herstellung und verwendung
IL112588A0 (en) Imidazo [1,2-a] quinoxalinone derivatives, their preparation and pharmaceutical compositions containing them
ES8607910A1 (es) Un procedimiento para la preparacion de nuevos derivados de feniletanamina
HUP9902606A2 (hu) Mátrix metalloproteináz inhibitorok
GB1505848A (en) 3,4-dicarboxycephalosporins and derivatives
IL99819A0 (en) Imidazole-2-yl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them
FR2191887A1 (en) 7-Substd 5-hydroxy-imidazo pyrimidines - antiinflammatories, and immuno-suppressives, from 2-aminoimidazoline and substd ethyl acetates
ES8404362A1 (es) Un procedimiento para preparar nuevos compuestos de cefem.